Mirum Pharmaceuticals MIRM 深 沪
等待开盘 07-08 09:30:00 美东时间
126.80
+4.890
+4.01%
华盛通- 最 高126.88
- 今 开123.60
- 成交量 25.68万股
- 最 低 118.11
- 昨 收 121.91
- 总市值 77.32亿
- 52周最高 126.88
- 市盈率 静 --
- 换手率 0.42%
- 52周最低 50.25
- 委 比 -95.35%
- 总股本 6098.12万
- 历史最高 126.88
- 量 比 0.70
- 振 幅 7.19%
- 历史最低 6.513
- 每 手 1
- 风险率 17.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多JP Morgan Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $125
JP Morgan analyst Jessica Fye maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target from $115 to $125.
07-02 22:30
U.S. RESEARCH ROUNDUP- Adobe, Nike, Watts Water Technologies
U.S. RESEARCH ROUNDUP- Adobe, Nike, Watts Water Technologies July 2 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Adobe, Nike and Watts Water Technologies on Thursday. HIGHLIGHTS * Adobe Inc ADBE.O : HSBC raises to buy
07-02 15:06
Mirum Pharmaceuticals MIRM走势强劲 其5.5%的涨幅能否进一步扩大
米鲁姆制药（MIRM）上一交易日收涨5.5%，报123.77美元，此前四周累计涨幅达17.8%，股价上行核心驱动为其在研药物zilurgisertib的II期临...
06-29 23:59
Mirum Shareholders Approve Directors, Auditors and Compensation
Mirum Pharmaceuticals ( ($MIRM) ) has shared an announcement. On June 15, 2026,...
06-19 05:01
美股大行评级 | 大摩再上调希捷科技和西部数据目标价；多家大行首予Lincoln买入评级
今日重点评级关注：HC Wainwright & Co.：维持Elicio Therapeutics"买入"评级，目标价从17美元升至23美元；Leerink Partners：维持SAB Biotherapeutics"跑赢大市"评级，目标价从7美元升至12美元
06-16 11:34
Mirum and Incyte's zilurgisertib shows positive Phase 2 data in FOP
Shares of Mirum Pharmaceuticals (MIRM) and Incyte (INCY) are in focus after the companies delivered positive pivotal Phase 2 data for their oral FOP candidate, zilurgisertib. Results from Cohort 1 of ...
06-15 14:38
美股大行评级 | 甲骨文绩后分歧大！5家上调，2家下调；Navan、Hinge Health、凯西通用获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从6美元升至10美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从14美元升至14.5美元
06-12 11:32
Morgan Stanley Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $150
Morgan Stanley analyst Michael Ulz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target from $140 to $150.
06-11 20:24
Mirum CFO Eric Bjerkholt disposes of common shares worth $468,720.88
Mirum CFO Eric Bjerkholt disposes of common shares worth $468,720.88 Mirum Pharmaceuticals CFO Eric Bjerkholt sold 5,000 common shares on June 8 at weighted average prices of USD 92.84 to USD 95.12. He reported 44,788 shares owned following the sales. Bjerkholt exercised 2,393 employee stock options
06-10 09:21
美股大行评级 | 潜在涨幅43%，慧与获11家大行集体上调目标价；最高300美元，Credo获9家大行集体上调目标价
今日重点评级关注：Ascendiant Capital：维持Genasys"买入"评级，目标价从5.5美元升至6美元；Citizens：维持Abivax"跑赢大市"评级，目标价从131美元升至187美元
06-03 11:17
